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Repopulation of surviving clonogenic tumour cells during the
course of fractionated radiotherapy (RT) is a critical factor in
determining tumour response and local control (Withers et al,
1988; Trott, 1990). To overcome tumour cell repopulation, a
variety of accelerated schedules of RT with a shortened overall
treatment time (OTT) were investigated. In our previous studies of
oesophageal squamous cell carcinomas, accelerated hyperfraction-
ation (AHF) significantly improved local control and survival
probabilities of stage II and III oesophageal cancer, and fractiona-
tion schema (AHF vs conventional fractionation (CF)) was a
significant variable on local control in the multivariate analysis
(Nishimura et al, 1994, 1997). However, both acute and late
toxicities were increased in patients treated with AHF. Thus, AHF
may not be feasible or beneficial for all patients with oesophageal
carcinomas. It is important to select patients who would benefit
from AHF before the start of RT.
Potential doubling time (Tpot) measured by flow cytometry
using bromodeoxyuridine (BrdU) or iododeoxyuridine (IdU) has
been regarded as a parameter of tumour cell proliferation. Several
clinical studies have been performed to reveal the relationship
between Tpot and local control or survival rates for patients treated
by RT. However, the results of these studies have been variable.
Some clinical studies indicated that the Tpot may be a predictor of
local control after RT in head and neck cancer (Awwad, 1992;
Corvo et al, 1993, 1995; Zackrisson et al, 1997) and in uterine
cervical cancer (Tsang et al, 1995; Bolger et al, 1996), while others
demonstrated that Tpot had no, or borderline, significance for local
control (Begg et al, 1992, 1995; Bourhis et al, 1996).
Recently, immunohistochemical staining of proliferation-
related antigens has been applied to the measurement of tumour
proliferation. This simple method has become widely prevalent as
new antibodies for formalin-fixed human tumours have become
commercially available. This technique can be used with archival
materials of the tumours, allowing retrospective studies to be
performed (Yu et al, 1992; Yu and Filipe, 1993). In addition,
immunohistochemical study is superior to BrdU labelling index
(LI) in that it is not necessary to administer any agent to patients.
Potential prognostic values of proliferating cell nuclear antigen
(PCNA) and Ki-67 have been studied extensively for many
tumour types (Yu et al, 1992; Yu and Filipe, 1993). PCNA is a
36 kDa acidic nuclear protein and has been recognized as a histo-
logic marker for the G1/S phase in the cell cycle. Ki-67 is a
proliferation-associated nuclear antigen and is expressed in all
cycling cells except for resting cells in the G0 phase.
The purpose of this study was to clarify the relationship of
immunohistochemical indices of PCNA and Ki-67 to local control
and survival in patients with oesophageal squamous cell carci-
nomas treated by definitive RT. In addition, whether these
immunohistochemical indices are useful in selecting a fractiona-
tion regimen was investigated.
MATERIALS AND METHODS
The formalin-fixed, paraffin-embedded sections of oesophageal
cancers were retrieved from the files of Kyoto University Hospital
and its two affiliated hospitals, Shizuoka City Hospital and Kyoto
Katsura Hospital. Between 1979 and 1996, 65 patients were iden-
tified who fulfilled the following criteria: (1) previously untreated
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Correspondence to: Y Okunosquamous cell carcinomas of the oesophagus; (2) treated by defin-
itive RT; (3) biopsy materials before RT were available for
immunohistochemical analysis. There were 53 males and 12
females, with a median age of 68 years old (range 46–87). Staging
was according to the International Union Against Cancer (UICC)
classification (1987). There were 12 stage I, 13 stage II, 22 stage
III and 18 stage IV oesophageal cancers. Details of the patients
and tumour characteristics are shown in Table 1. The clinicopatho-
logical parameters of all 65 patients were analysed in relation to
immunohistochemical results, although 18 stage IV patients were
excluded from the analysis of local control and cause-specific
survival. Generally speaking, patients with stage IV disease are
not candidates for definitive radiotherapy (RT), and their fields
and total doses of radiation are smaller than those for patients with
stages I–III. Therefore, patients with stage IV are excluded from
the analysis of local control and cause-specific survival.
Radiation therapy
All of the patients were treated by definitive RT of more than 58
Gy. The details of the radiation methods were described previously
(Nishimura et al, 1994). Briefly, AHF for oesophageal cancer was
started at Kyoto University Hospital and its affiliated hospitals in
1989. Thereafter, most untreated oesophageal cancers of stages II
and III were treated with AHF. Among the 65 patients in this
analysis, 18 patients were treated with AHF. Two different
schemes were used as twice-a-day (b.i.d.) protocols. Patients were
treated with concomitant boosts using b.i.d. irradiation (1.8–
1.2 Gy plus 1.1–1.2 Gy) with fractionation interval of 5–6 h. In the
other b.i.d. protocol, a large radiation field encompassing the gross
clinical disease plus sufficient margin was irradiated b.i.d. at 5- or
6-h intervals with the same fraction size of 1.5 Gy. At a total dose
of 39–45 Gy, the radiation field was reduced to the gross clinical
disease and a boost was given to the total dose of 63–69 Gy.
All of the patients treated before 1989, and patients who refused
AHF after 1989, were treated with CF. Forty-seven patients were
treated with CF. For these patients, external RT was given by daily
doses of 1.8–2.0 Gy to a total dose of 50–70 Gy. Patients with
slight to moderate residual tumours at the end of external RT were
selectively treated with intraluminal high-dose-rate brachytherapy
(IBT). For these patients, IBT was given once a week following
external RT. The reference point of dose calculation was at 5 mm
below the surface of the oesophageal mucosa.
Forty-seven patients with disease in stages I–III were divided
into two groups according to fractionation schemes. Thirty-two
patients were treated with CF, and the remaining 15 patients were
treated with AHF. All but one patient with stage I disease were
treated with CF. For the CF group, external RT doses ranged from
50 Gy to 70 Gy (mean 62 Gy), and 11 patients (34%) were treated
with IBT following external RT. Mean RT dose for IBT was
9.6 Gy by one to four fractions. The patients treated with AHF
received external RT doses of 63–69 Gy (mean 66 Gy). Three
patients were treated with IBT as boost therapy following AHF.
External RT dose for the AHF group was significantly higher than
that for the CF group (P , 0.05). However, total RT dose (external
RT plus IBT) was not significantly different between the two
groups. OTT for the external RT of the AHF group ranged from 27
to 49 days with a median of 35 days, while the median of OTT in
the CF group was 52 days. Thus, the shortening of OTT by
approximately 2 weeks could be achieved by AHF. The difference
in OTT between the two groups was significant (P , 0.003).
Chemotherapy
Concomitant chemotherapy was given to two patients in the AHF
group, while two patients in the CF group received concomitant
chemotherapy. Cisplatin (80–120 mg in total) plus 5-fluorouracil
(5-FU) (4000 mg in total) were given during external RT for three
patients, and cisplatin alone (200 mg in total) was given to one
patient.
Evaluation of tumour response
Responses of the primary tumour to irradiation were assessed by
serial oesophagography, endoscopy and biopsies. Oesophagography
and/or endoscopy was performed every 3–4 months for asymptotic
patients, and any clinically suspected tumour recurrence required
biopsy and histopathological proof. Computerized tomography
(CT) scans were obtained at 3- to 6-month intervals for most recent
patients, and those were used for evaluation of any recurrence of
primary tumours and regional lymph nodes. Local control was
defined as neither clinical nor pathological evidence of a primary
tumour or lymph nodes recurrence in the initial field of RT.
Immunohistochemical staining
All specimens were formalin-fixed, paraffin-embedded sections
obtained by endoscopic biopsies before RT. The sections were
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Table 1 Patients and tumour characteristics
No. of patients 65
Sex (male/female) 53/12
Age (median) 46–87 (68)
Site
Cervical 5
Upper 12
Middle 37
Lower 11
Histology (differentiation)
Well 23
Moderate 34
Poor 8
Tumour length
, 5c m 2 6
³ 5c m 3 9
Stage (UICC, 1987)
I1 2
II 13
III 22
IV 18
T classification
11 2
28
32 5
42 0
N classification
02 1
13 9
c 5
M classification
04 7
11 8PCNA and Ki-67 for eosophageal cancer 389
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Table 2 PCNA labelling index (LI) and clinicopathologic parameters
PCNA LI
Mean 6 s.d. Median P-value
No. of patients 65
Sex
Male 53 50 6 13 52 NS
Female 12 48 6 13 50
Site
Cervical 5 46 6 15 44 NS
Thoracic 60 50 6 13 53
Histology (differentiation)
Well 23 51 6 12 54 NS
Moderate 34 48 6 13 51
Poor 8 52 6 13 53
Tumour length
, 5 cm 26 50 6 12 52 NS
³ 5 cm 39 49 6 14 53
Stage (UICC, 1987)
I 12 54 6  75 6 N S
II–IV 53 49 6 14 52
T classification
1, 2 20 50 6 12 53 NS
3, 4 45 50 6 13 53
N classification
0 21 50 6 14 54 NS
1 39 49 6 12 52
c 5 54 6 10 55
M classification
0 48 49 6 13 52 NS
1 17 51 6 12 53
s.d., standard deviation; NS, not significant.
Table 3 Ki-67 labelling index (LI) and clinicopathologic parameters
Ki-67 LI
Mean 6 s.d. Median P-value
No. of patients 65
Sex
Male 53 44 6 16 46 NS
Female 12 37 6 17 33
Site
Cervical 5 26 6 13 22 , 0.05
Thoracic 60 44 6 16 46
Histology (differentiation)
Well 23 42 6 13 41 NS
Moderate 34 44 6 18 46
Poor 8 43 6 16 48
Tumour length
, 5 cm 26 48 6 14 49 , 0.05
³ 5 cm 39 40 6 17 39
Stage (UICC, 1987)
I 12 49 6 94 9 , 0.05
II–IV 53 42 6 17 43
T classification
1, 2 20 49 6 11 49 , 0.05
3, 4 45 40 6 18 40
N classification
0 21 44 6 16 46 NS
1 39 43 6 17 45
c 5 36 6 11 32
M classification
0 48 42 6 17 46 NS
1 17 44 6 15 45
s.d., standard deviation; NS, not significant.stained by the labelled streptavidin biotin (LSAB) method using a
Dako LSAB kit (Dako, Carpinteria, CA, USA). Anti-PCNA mouse
monoclonal antibody, PC10 (Cat# NA03, Oncogene Science,
Cambridge, MA, USA) and anti-Ki-67 mouse monoclonal anti-
body, MM1 (NCL–Ki67–MM1, Novocastra Laboratories, UK)
were used as the primary antibodies. For retrieval of antigenicity,
microwave irradiation in 10 mM sodium citrate buffer at 500 W for
15 min was given for PC10, and autoclave in the target retrieval
solution (Dako, Carpinteria, CA, USA) at 1218C for 15 min was
processed for MM1. Endogenous peroxide activity was blocked
with 3% hydrogen peroxide at room temperature for 10 min. After
washing with phosphate-buffered saline (PBS), the sections were
incubated with 10% normal swine serum in PBS for 30 min. After
that, the sections were incubated with a 1:200 dilution of PC10 at
room temperature for 60 min, or with a 1:100 dilution of MM1
overnight at 48C. The primary antibodies were localized by sequen-
tial application of biotylinated anti-mouse IgG gout immunoglo-
bins, streptavidin–peroxide conjugate (Dako, Carpinteria, CA,
USA), and diaminobenzidine with 0.03% hydrogen peroxide. The
sections were counterstained with haematoxylin and mounted.
Control sections were prepared by performing immunohistochem-
istry using non-immune mouse g-globulin instead of the primary
antibodies.
Quantitative analysis of immunostaining results
All specimens from the 65 patients were reviewed by a pathologist
to confirm the diagnosis and the differentiation. PCNA and Ki-67
LIs were calculated as the percent of PCNA- and Ki-67-positive
cancer cells by counting more than 1000 cancer cells of more than
three fields of a specimen on 3 400 magnification microscopy
without knowing any clinical information. Only strong nuclear
staining was regarded as positive, and weak nuclear or cyto-
plasmic staining was regarded as negative.
Statistical methods
Local control and cause-specific survival were calculated from the
first date of external RT. Cause-specific survival considered deaths
due only to oesophageal cancer, while all other patients who died
of intercurrent diseases were counted as withdrawn alive.
Local control and survival were plotted using the Kaplan–Meier
method with statistical significance assessed by the log-rank test.
The c2 test with Yates correction and Student’s t-test were used to
evaluate the differences in the distribution of pretreatment and
treatment parameters.
The Cox proportional hazards model was used to evaluate the
significance of prognostic variables on local control. The Cox
model was performed using Stat View, version 4.5 (Abacus
Concepts, Inc., NC, USA). In the Cox model, 47 patients with
stages I–III were included in the analysis of the effect of covariates
on local control. The final model considers only those variables
that were statistically significant at the 5% level in stepwise
regression.
RESULTS
Staining of PCNA and Ki-67
Both PCNA and Ki-67 staining were identified in the nuclei of
both neoplastic and non-neoplastic cells. The nuclei of the basal
and parabasal cells were positive for the markers. In the cancer
cells, there were heterogeneous PCNA and Ki-67 staining. In well-
differentiated oesophageal cancers, this staining was noted more
dominantly in the periphery area of the tumour nest than in the
central keratinizing area, while there was a more diffuse staining
in poorly differentiated cancers.
The PCNA LI ranged from 20% to 72%, and its mean, median
and standard deviation (s.d.) were 50%, 52% and 13% respec-
tively. The relationship of the PCNA LI to clinicopathologic para-
meters is shown in Table 2. The PCNA LI had no significant
relationship to the age or sex of the patients, tumour location,
differentiation, tumour length, stage and tumour, node and metas-
tasis (TNM) classification of the lesions. Thus, PCNA LI was
independent of known prognostic factors on local control proba-
bility for oesophageal cancers.
The Ki-67 LI of the 65 patients ranged from 3% to 79%, and its
mean, median and s.d. were 43%, 45% and 16% respectively. The
relationship of the Ki-67 LI to clinicopathologic parameters is
shown in Table 3. The Ki-67 LI had no significant relationship to
the sex of the patients, tumour differentiation, and N- and M-clas-
sification. However, the Ki-67 LI was significantly associated with
tumour location, clinical stage and T classification. The Ki-67 LI
of the cervical oesophageal carcinomas was significantly lower
than that of the thoracic lesions (P , 0.05). The Ki-67 LI of the
patients with tumour lengths of , 5 cm were significantly higher
than that of the patients with tumour lengths of ³ 5 cm (P , 0.05).
The Ki-67 LI of the patients with T1,2 or stage I disease were
significantly higher than that of the patients with T3,4 or stages
II–IV diseases (both P , 0.05).
To evaluate the relationship between PCNA LI and Ki-67 LI,
these LIs were plotted for each tumour (Figure 1). A weak but
significant correlation was observed between PCNA LI and Ki-67
LI (R^2 5 0.078, P 5 0.024).
Local control and survival rates according to PCNA LI
For the 47 patients with stage I–III disease, the relationship
between the PCNA LI and local control or cause-specific survival
rates was analysed. The patients were divided into two groups
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Figure 1 Relationship between the PCNA LI and the Ki-67 LI. There was a
weak but significant correlation between them (R^2 5 0.078, P 5 0.0240)according to the median PCNA LI: group A was the PCNA LI of
less than 52% (n 5 21), and group B was the LI of more than or
equal to 52% (n 5 26). There was no difference in the clinico-
pathologic parameters between groups A and B (Table 4). Figure 2
shows local control and cause-specific survival of stage I–III
patients according to the PCNA LI. The 3-year local control rates
for groups A and B were 24% and 56% respectively. The local
control probability of group B was significantly higher than that of
group A (P , 0.05). The 3-year cause-specific survival rates for
groups A and B were 43% and 56% respectively. Although the
survival rate was better in group B than in group A, the difference
was not significant.
Local control and survival rates according to Ki-67 LI
Similar analysis was performed for the Ki-67 LI. The 47 patients
with stage I–III disease were divided into two groups: group C was
the Ki-67 LI of less than 45% (n 5 21) and group D was the LI
more than or equal to 45% (n 5 26). There was no difference in the
clinicopathologic parameters between groups C and D (Table 4).
Figure 3 shows local control probability and cause-specific
survival according to the Ki-67 LI. The 3-year local control proba-
bilities for group C and group D were 21% and 51% respectively.
The local control probability of group D was significantly higher
than that of group C (P , 0.05). The 3-year cause-specific survival
PCNA and Ki-67 for eosophageal cancer 391
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Table 4 Tumour characteristics according to groups
Groups Group A Difference Group B Group C Difference Group D
No. of patients 21 26 21 26
Histology (differentiation)
Well 8 NS 11 9 NS 10
Moderate 11 12 10 13
Poor 2 3 2 3
Tumour length 5.6 6 2.9 NS 5.3 6 3.2 6.2 6 3.0 NS 4.9 6 2.9
Stage (UICC, 1987)
I 4 NS 8 2 NS 10
II, III 17 18 19 16
T classification
1, 2 8 NS 11 5 NS 14
3, 4 13 15 16 12
N classification
1 10 NS 11 8 NS 13
0 9 12 9 12
c 23 41
Group A: patients with PCNA LI of less than 52%; Group B: patients with PCNA LI of more than or equal to 52%; Group C: patients with Ki-67 LI of less than
45%; Group D: patients with Ki-67 LI of more than or equal to 45% NS, not significant
100
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50
40
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0
012345
Year
PCNA LI³ 52%
PCNA LI<52%
P <0.05
A
Figure 2 (A) Local control probability and (B) cause-specific survival according to PCNA LI. Local control probability of the patients with PCNA LI of ³ 52%
was significantly higher than that of the patients with PCNA LI of , 52% (P , 0.05). There was no significant difference in cause-specific survival between the
two groups
Bfor group C and group D were 38% and 60% respectively. There
was no difference in the cause-specific survival between groups C
and D.
Local control rate according to fractionation schemes
To assess the impact of the fractionation on local control, the
patients were divided into two groups according to fractionation
schemes, and the relationship between the LIs and local control
probabilities was analysed in each fractionation group. Figure 4
shows the relationship between local control probability and the
PCNA LI according to fractionation regimen. For the patients
treated with CF, the local control probability of the tumours with
high PCNA LI was significantly higher than that with low PCNA
LI (P , 0.05), although there was no significant difference in local
control probability according to the PCNA LI for the patients
treated with AHF.
Figure 5 shows the correlation between local control probability
and the Ki-67 LI according to the fractionation regimen. For the
patients treated with CF, the patients with the high Ki-67 LI had
significantly better local control probability than those with the
low Ki-67 LI (P , 0.05). For the patients treated with AHF,
however, there was no significant difference in local control
probability according to Ki-67 LI.
The multivariate analysis
The results of the multivariate analysis using the Cox proportional
hazards model are shown in Table 5. The prognostic factors which
influenced local control significantly in the univariate analysis
were as follows: tumour length (, 5 cm vs ³ 5 cm; P , 0.05),
T-stage (T1,2 vs T3,4; P , 0.005), N-stage (N0 vs N1; P , 0.02),
clinical stage (stage I vs stages II–III; P , 0.05), PCNA LI
(, 52% vs ³ 52%; P , 0.05), and Ki-67 LI (, 45% vs ³ 45%
P , 0.05). Because there was significant correlation between
T-stage and length, or between clinical stage and length, only
T-stage was included in the multivariate analysis among these
prognostic factors. N-stage was excluded because N-stages of five
patients were unknown because of the lack of the pretreatment
chest CT scan. Thus, the following four factors that may have
contributed to local control were considered simultaneously in the
initial mode of the Cox proportional hazards model. The variables
included were T-stage (T1,2 vs T3,4), fractionation schedule (CF
vs AHF), PCNA LI (, 52% vs ³ 52%) and Ki-67 LI (, 45%
vs ³ 45%). The significant factors in the initial model were T-stage
(P 5 0.0054) and PCNA LI (P 5 0.0488). In the final model using
a stepwise regression procedure, T-stage (P 5 0.0056) and PCNA
LI (P 5 0.0332) were also significant factors for local control. As
no significant correlation was found between T-stage and PCNA
LI (Table 2), these two variables were independent prognostic
factor for local control.
DISCUSSION
Measurement of Tpot was used as a predictive value of local
control or survival in patients treated by RT and to select an appro-
priate fractionation regimen in head and neck carcinoma (Begg et
al, 1990, 1992; Awwad, 1992; Corvo et al, 1993, 1995; Zackrisson
et al, 1997) and in uterine cervical cancer (Tsang et al, 1995;
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Figure 3 (A) Local control probability and (B) cause-specific survival according to Ki-67 LI. Local control probability of the patients with Ki-67 of LI ³ 45% was
significantly higher than that of the patients with Ki-67 LI of , 45% (P , 0.05). There was no significant difference in cause-specific survival between the two
groups
Figure 4 Relationship between local control probability and the PCNA LI
according to fractionation scheme. For the patients treated with conventional
fractionation (CF), the local control probability of the tumours with the LI of
³ 52% were significantly higher than those with the LI of , 52% (P , 0.05).
No significant difference was observed according to the PCNA LI for patients
treated with AHFBolger et al, 1996). In a preliminary analysis of the results of the
EORTC trial (Begg et al, 1990), patients with short Tpot tumours
had poor local control if given CF. However, in a subsequent
analysis, the difference in local control according to the Tpot
was not significant (Begg et al, 1992; Begg, 1995). Recently,
Zackrisson et al demonstrated that Tpot and nodal status were
significant variables on local control in head and neck cancer
patients treated by conventional radiotherapy in the multivariate
analysis (Zackrisson et al, 1997). Thus, the results of clinical
studies on Tpot are still controversial.
PCNA LI and Ki-67 LI have been regarded as parameters of
tumour proliferation. In most series of patients undergoing surgery
for oesophageal squamous cell carcinomas (Youssef et al, 1995;
Kinugasa et al, 1996; Lam et al, 1996), the groups with a high
PCNA or a high Ki-67 index showed lower survival rates. For
example, Lam et al (1996) analysed PCNA and Ki-67 LIs for surgi-
cally resected oesophageal squamous cell carcinoma, and they
found that patients with Ki-67 LI of , 30% had better survival rates
than those with LI of . 30% in stage III disease. On the other hand,
for patients treated mainly by RT, the tumours with high PCNA LI
or Ki-67 LI showed good local control in squamous cell carcinomas
of the head and neck (Raybaud et al, 1997) and uterine cervical
cancer (Oka et al, 1992; Nakano and Oka, 1993; Nakano et al,
1997). In the present study, patients with a PCNA LI of ³ 52% or
those with a Ki-67 LI of ³ 45% showed a lower local recurrence
rate. This result may conflict with the results of Tpot studies. One
explanation is that Tpot and LIs of Ki-67 and PCNA represent
different aspects of the tumour proliferation. Growth fraction and
cell cycle time are major independent tumour proliferation charac-
teristics. Ki-67 and PCNA LIs reflect mainly growth fraction, while
Tpot reflects gross proliferation activity including both growth frac-
tion and cell cycle time. Good local control rate for the patients with
high PCNA LI or high Ki-67 LI treated by RT may be attributable to
a high population of cycling cells. These cycling cells are generally
more radiosensitive than quiescent cells (Rodriguez et al, 1988;
Mendonca et al, 1989; Masunaga et al, 1991).
AHF has been considered to be more effective for rapidly prolif-
erating tumours. Therefore, initially we expected that local control
probabilities of patients with high LIs was poor and AHF may be
more effective for tumours with high LIs than for those with low
LIs. However, the results obtained contradicted our hypothesis;
local control probabilities of patients with low PCNA LI or low
Ki-67 LI were poor. Although initial local control rate within 6–12
months of RT was higher in the AHF group than in the CF group
for tumours with low LIs (Figures 4 and 5), AHF did not improve
the ultimate local control probability significantly for these
tumours. Although the number of patients analysed was too small
to draw any conclusions, AHF may not be effective for tumours
with low LIs or tumours with many quiescent cells. As the present
study did not measure the speed of tumour proliferation or Tpot,
our results do not imply that AHF is not effective for tumour with
rapid proliferation.
In the present study, both PCNA LI and Ki-67 LI had significant
correlation with local control probability (both P , 0.05) in the
univariate analysis, and PCNA LI was also significant for local
control in the multivariate analysis. In addition, PCNA LI is superior
to Ki-67 LI in that PCNA LI was independent of known prognostic
factors on local control probability for oesophageal cancers (Table
2). On the other hand, there was significant difference in Ki-67 LI
according to tumour length, clinical stage, and T classification
(Table 3). Poor local control probability of the patients with low
Ki-67 LI may be associated with a long tumour length and/or
advanced T stage (Table 4). Decrease of Ki-67 LI in long and/or
advanced tumours may be attributable to reduced prolifera-
tive activity and/or loss of Ki-67 antigen expression due to the
worsening of the intratumoural environment in the advanced
tumours. It is natural that tumour proliferation is influenced by the
intratumoural environment. Proliferation is suppressed when either
nutrition or oxygen is lacking. For example, Porschen et al (1994)
demonstrated that Ki-67 immunostaining of tumour cells decreased
with increasing distance from the surrounding capillaries in
oesophageal squamous cell carcinomas. Veheijen et al (1989)
reported a loss of Ki-67 antigen reactivity in nutritionally deprived
cells which were still in S, G2 or M phase as measured by flow
PCNA and Ki-67 for eosophageal cancer 393
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Table 5 Results of multivariate analysis using Cox proportional hazard model: prognostic variables for local control
Variables Initial model Final model
(P-values) (stepwise regression)
Fractionation (AHF vs. CF) 0.3102
T stage (T1, 2 vs T3, 4) 0.0054 0.0056
PCNA LI (, 52% vs ³ 52%) 0.0488 0.0332
Ki-67 LI (, 45% vs ³ 45%) 0.3882
AHF, accelerated hyperfractionation; CF, conventional fractionation.
100
90
80
70
60
50
40
30
20
10
0
012345
Year
P<0.05
CF, Ki-67 LI <45% n =15
CF, Ki-67 LI ³ 45% n =17
AHF, Ki-67 LI <45% n =6
AHF, Ki-67 LI ³ 45% n =9
Figure 5 Relationship between local control probability and the Ki-67 LI
according to fractionation scheme. For the patients treated with conventional
fractionation (CF), the local control probability of the tumours the LI of ³ 45%
were significantly higher than those with the LI of , 45% (P , 0.05). No
significant difference was observed according to the PCNA LI for patients
treated with AHFcytometry. Tsurusawa and Fujimoto (1995) reported a down-regula-
tion of Ki-67 antigen expression to an undetectable level in tumour
cells with a relatively long G1 duration. In these conditions, Ki-67
LI may be measured lower than the true growth fraction.
In terms of staining technique, Ki-67 LI is superior to PCNA LI.
Staining of Ki-67 was easier to interpret than that of PCNA
because of less background staining and stronger and more
uniform positive stains. The need for caution has been noted when
measuring PCNA LI using antibody PC10 on formalin-fixed
human tumours (Yu et al, 1992; Coltrera et al, 1993; McCormick
et al, 1993a; Yu and Filipe, 1993) including: (1) at least two intra-
cellular forms of PCNA exist – a replicon-associated form and a
non-associated form that is present in almost all cycling cells
(Bravo and Macdonald, 1987); (2) the PCNA staining was found
to be highly influenced by the primary antibody dilution and the
fixation time, and it lacks a clear plateau (Wolf and Dittrich, 1992;
Coltrera et al, 1993; McCormick et al, 1993b); (3) the long half-
life of PCNA (approximately 20 h), results in stain remaining in
cells which have recently left the cell cycle (Bravo and
Macdonald, 1987). Therefore, several investigators recommended
that Ki-67 LI is a reliable tool for the measurement of proliferation
activity (Yu et al, 1992; McCormick et al, 1993a; Yu and Filipe,
1993) and is suitable for multi-institute cooperative studies. In
those situations, wide variations in fixation times, formaline
composition and antibody dilution among different laboratories
could result in significant inter-laboratory differences.
In the present study, PC10 was used as the primary antibody for
the measurement of the PCNA LI in the formalin-fixed tissues.
Therefore, the PCNA LI in this study could include both a replica-
tion-associated form and non-associated form. That may be why
there was only a weak correlation between PCNA LI and Ki-67 LI
(R^2 5 0.078, P 5 0.0240). In spite of the technical problem
mentioned above, there was a significant correlation between the
PCNA LI and local control probabilities (P , 0.05) at least by our
laboratory method. The characteristics in our method of staining
and counting are as follows: (1) microwave irradiation was
processed for retrieval of antigenicity, (2) only strong nuclear
staining was judged by positive, and weak nuclear or cystoplasmic
staining was as negative. Antigen retrieval process may overcome
the problem of the various level of loss of antigenicity due to the
various fixation times (Greenwell et al, 1991). Strong nuclear
staining may reflect a replication-associated from of PCNA (Yu et
al, 1995). In the studies where alcohol was used as a fixative, a
good correlation between PCNA expression and BrdU labelling
indices or the flow cytometrically determined S phase fraction is
reported because the replication-associated from of PCNA
remains in the cell after alcoholic fixation (Coltrera et al,
1993;Tinnemans et al, 1995). In a prospective study on PCNA
staining, alcohol fixation may be better than formalin fixation.
CONCLUSIONS
In the univariate analysis, PCNA LI and Ki-67 LI of oesophageal
squamous cell carcinomas had a significant impact on local
control probability of oesophageal cancer treated by definitive RT.
PCNA LI was independent of known prognostic variables, and
was also a significant variable on local control in the multivariate
analysis. For the patients with low PCNA LI or Ki-67 LI, RT
by CF regimen was insufficient. For these poor prognostic
oesophageal cancers, strong regimens of RT may be necessary,
although AHF did not improve significantly the local control prob-
ability in the present analysis.
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